Gwendolyn BinderExecutive VP, Science & Technology at Cabaletta Bio
Dr. Binder serves as Executive Vice President, Science and Technology at Cabaletta Bio, which a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Prior to joining Cabaletta, Dr. Binder was the Chief Technology Officer of Adaptimmune Therapeutics Plc, where she first established and led capabilities in manufacturing, correlative science, compliance, regulatory and clinical operations. She later went on to build the translational sciences, and manufacturing and quality teams leading to opening of an onsite manufacturing facility, and then assumed leadership of the research organization. Earlier in her career, Dr. Binder served as Director of Operations for the Translational Research Program at the University of Pennsylvania, where she participated in multiple engineered T cell therapy clinical programs in HIV and oncology including the data generation and IND drafting for the CD19 CAR program (later licensed to Novartis) under the leadership of Drs. Carl June. Prior to that, she was the director of scientific affairs at VIRxSYS Corporation. Dr. Binder received her Ph.D. from the Johns Hopkins University School of Medicine and her B.A. from Wells College.